Compare BIO-TECHNE Corp (TECH) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Western Alliance Bancorporation — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Western Alliance Bancorporation trades at $76.21 (market cap $8.24B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Western Alliance Bancorporation pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Western Alliance Bancorporation for 3 Days on average.
| TECH | WAL | |
|---|---|---|
Market Cap | $11.36B | $8.24B |
Volume | 5,390,331 | 1,387,161 |
Sector | Health | Financials |
52-Week High | $72.61 | $96.08 |
52-Week Low | $43.31 | $66.70 |
Typical Hold Time | 63 Days | 3 Days |
Enterprise Value | $11.39B | $9.76B |
Dividend Yield | 0.44% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Western Alliance Bancorporation (WAL) trades at $74.35, down 2.29% today, with a bearish technical signal but strong fundamentals including a P/E of 8.52 and net income margin of 25.43%. Recent Q2 2026 earnings missed EPS estimates at $2.36, though revenue and profitability trends remain positive. The company launched WA VenueX, an institutional financial platform, and announced a $0.42 dividend for H2-2026.
Outlook is mixed: analyst consensus is strongly bullish with a $84.33 price target, but technical indicators signal near-term pressure. Key risks include interest rate sensitivity and regulatory changes, while institutional buying and solid valuation metrics support long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
